|
Licensing & Acquisition (L&A)
Trinity acts as a trusted partner to many clients in the realm of business development, licensing and mergers/acquisition. We support all aspects of the business development process, ranging from opportunity identification and evaluation to deal negotiation and optimization. We have experience on both “sides of the table,” from small venture-backed companies who are seeking partnerships to mid- and large-cap companies who are in the process of setting their strategic direction in new markets.
We provide meticulous, objective and actionable assessments of US and global licensing and acquisition opportunities. We pride ourselves on a rapid response to client needs and on our record of delivering top quality work in high-pressure situations for difficult projects. Trinity has completed hundreds of assessments in a vast array of therapeutic areas and technology platforms, including short- (filed/launched), mid- (Phase IIb - III) and long-term (preclinical - Phase IIa) opportunities. The breadth of our expertise makes us an immediate contributor with minimal lag time.
At Trinity, we combine proficiency in science and business strategy, resulting in recommendations that are balanced and comprehensive in technical and commercial attributes. We challenge our clients to consider all aspects of potential deals, including each of the 3C’s: Clinical value-add, Commercial opportunity and Company fit. Using this framework, we are able to systematically and effectively evaluate diverse opportunities. Because of the increasing competitiveness of L&A in the pharmaceutical industry, independent third-party evaluation is essential for most, if not all, opportunities.
Questions for Trinity
What specialty products are available in phase II and higher that best complement our product portfolio?
What are the key drivers that underpin the true value of a licensing opportunity?
As a small R&D focused company how do we best position our asset for outlicense?
How do we account for long term commercial and clinical risk in the valuation of a potential acquisition?
|
